A ‘landmark’ clinical trial called the AMP study launches on three continents to test HIV-blocking super antibodies
April 7, 2016
| By Mary Engel / Fred Hutch News Service
“It’s not often that you know that you’re starting a landmark study," says Dr. Larry Corey, founder and director of the HIV Vaccine Trials Network. Two of the world’s top HIV prevention clinical trial networks have joined forces to test an experimental antibody that could potentially protect people from infection by almost all strains of the rapidly mutating AIDS virus.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.